InnovationsKapital Secures SEK 1 Billion for New Investments.

STOCKHOLM, Sweden -- InnovationsKapital, a well established independent early stage venture capital firm, is pleased to announce the closing of the fourth InnKap fund - InnKap 4 Partners. InnovationsKapital's aggregated capital under management now amounts to EUR 317 million.

As with previous funds, InnKap 4 Partners will focus on investing in innovative start-up and early stage growth companies operating in the Nordic region and active in the ICT and Healthcare & Life Sciences market sectors. Since 1994, InnovationsKapital has completed 56 investments, earned an excellent reputation and is now a preferred venture capital investor for top entrepreneurs.

"We are delighted that InnKap 4 Partners has succeeded in attracting so many respected international investors. We owe this success to the solid support from our loyal long-term investors and are pleased to see so many of them taking part in this new fund," says Staffan Ingeborn, Managing Investment Director at InnovationsKapital Nordic Advisors AB.

Committed capital of EUR 113 million has been raised from a broad mix of Swedish and international investors, including 70 percent of the total from previous investors. Previous investors include Access Capital Partners, Chalmers University of Technology, The First Swedish National Pension Fund, The Third Swedish National Pension Fund, W Capital and The Wellcome Trust. Among the new investors are BP Pension Fund, DnB NOR, Etera, KLP Insurance and Wega Support. In total, the fund has about twenty investors from Europe and the US, with a majority of commitments coming from non-Swedish funds.

"The investors have recognised our attractive market position and consistency in terms of track record and proprietary deal access. With our experience from previous funds, coupled with our close co-operation with portfolio companies and our extensive international network, we will help our portfolio companies expand in the global market," says Peder Holm, Investment Director in the ICT team at InnovationsKapital.

The strong deal flow has been confirmed by two new investments in the fund - Ludesi AB and Action Pharma A/S. Ludesi is a global provider of bioinformatics solutions to the life science industry and Action Pharma is dedicated to the discovery and development of novel drugs with significant therapeutic improvement within organ protection in severe cardiovascular diseases.

"The high quality investors in this fund recognize InnovationsKapital's ability to identify promising healthcare/life science companies and supply them with access to the scientific, capital and management resources critical for success," says Ulf Tossman, Investment Director in the Healthcare/Life Science team of InnovationsKapital.

InnovationsKapital has a solid track record. During 2006, Carmen Systems and Kreatel Communications have been sold successfully to Boeing and Motorola respectively.

Gothenburg/Stockholm, October 6, 2006

InnovationsKapital Nordic Advisors AB

About InnovationsKaptial

InnovationsKapital was founded in 1994 and is a private and independent early stage venture capital firm for innovative growth companies. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences - dynamic sectors that are rapidly expanding and where Nordic research plays an important role. To date, more than 55 investments have made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Formex and Kreatel Communications. InnovationsKapital advises four venture capital funds aggregating EUR 317 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors.

Further information about InnovationsKapital can be found at www.innkap.se

This information was brought to you by Waymaker http://www.waymaker.net